Editorial Commentary
Slaying the real giants in the war on chronic lymphocytic leukemia
Chinese Clinical Oncology
2022;
11
(5)
:34
.
(31 October 2022)
Commentary on “Elective upper-neck versus whole-neck irradiation of the uninvolved neck in patients with nasopharyngeal carcinoma: an open-label, non-inferiority, multicentre, randomised phase 3 trial”
Chinese Clinical Oncology
2022;
11
(5)
:35
.
(31 October 2022)
First-line treatment with nivolumab and chemotherapy for metastatic gastric cancer in East Asia is not supported by results of the ATTRACTION-4 trial
Chinese Clinical Oncology
2022;
11
(5)
:36
.
(31 October 2022)
Pembrolizumab in metastatic mismatch repair deficient colorectal cancer: the beginning of a journey into the land of immunotherapies for all cancers
Chinese Clinical Oncology
2022;
11
(5)
:37
.
(31 October 2022)
Review Article
Radiotherapy for elderly patients with glioblastoma: an assessment of hypofractionation and modern treatment techniques
Chinese Clinical Oncology
2022;
11
(5)
:38
.
(31 October 2022)
The role of proximal gastrectomy in gastric cancer
Chinese Clinical Oncology
2022;
11
(5)
:39
.
(31 October 2022)
Tumor treating fields with radiation for glioblastoma: a narrative review
Chinese Clinical Oncology
2022;
11
(5)
:40
.
(31 October 2022)
Interviews with Outstanding Guest Editors1
Interview with Prof. Naoto T. Ueno, an inflammatory breast cancer expert
Chinese Clinical Oncology
2022;
11
(5)
:41
.
(31 October 2022)
Disclosure:
1. The series “Interviews with Outstanding Guest Editors” was commissioned by the editorial office, Chinese Clinical Oncology without any funding or sponsorship